Influence of Levocarnitin Treatment during a Stable Ischemic Heart Disease in Patients with Non-Alcoholic Fatty Liver Disease and Obesity
Journal Title: Український журнал медицини, біології та спорту - Year 2017, Vol 6, Issue 4
Abstract
Metabolic syndrome which is accompanied by excess body weight is a predictor of ischemic myocardial defeat in ischemic heart disease (IHD) and non-alcoholic fatty liver disease (NAFLD). Among the medicines that provide the normalization of metabolic status, correcting dyslipidemia, we would like to emphasize levocarnitine, which has anabolic effect, reduces the main metabolism, and has antihypoxic, lipid metabolism stimulating pharmacological effect. The purpose of the study is to determine the effect of levocarnitine on the progression of IHD in combination with NAFLD and obesity. Materials and methods. The surveyed patients (68 patients with an average age of 70.32 ± 6.71 years, 0.90 (M ± SEM; SD)) were divided into two groups: the main group and the comparison group. The main group consisted of 35 patients who received levocarnitine at a dose of 20 mg/kg/day intravenously for 10 days during the period of stay in the hospital, and subsequently on the stage of outpatient treatment continued the therapy per os – 1g 2 twice a day at the background of the standard IHD pharmacotherapy for another 21 days. The control group consisted of 33 patients who received exclusively standard IHD therapy. In both groups, in addition to the general clinical trial, daily monitoring of the ECG was performed (before and after 1 month of treatment) using the Holter system "LABTECH Ltd", software version V4.04.RC14), determination of lipidogram indicators (total chol esterol level (TCL), Triglycerides (TG), low-density lipoprotein (LDL-C) and high density (HDL-C), an atherogenicity index (AI)). The presence of NAFLD (fatty liver infiltration) was diagnosed with ultrasound examination of the abdominal organs on the Logiq F8 («General Electric») apparatus. Results and discussions. As a result of the study, significant decrease in the number of episodes and duration of ischemia periods per day in all patients and a tendency to decrease of cardiac rhythm disturbance in the background of treatment with a significant advantage in the group receiving additionally levocarnitine was noticed.
Authors and Affiliations
T. Shevchenko, S. Sorokina, I. Kudrya, O. Shaposhnyk
Keywords
Related Articles
- EP ID EP273387
- DOI -
- Views 78
- Downloads 0
Main Vectors of Medical Rehabilitation in Diaphyseal Fractures Treatment
Current study is based on a retrospective analysis of 68 patients treated at the traumatology clinic of Transkarpathian Regional Clinical Hospital named after A. Novak between 2015 and 2017. Their diagnosis was diaphysea...
FEATURES OF CLINICAL PICTURES OF THE MOUTH AND PSYCHOLOGICAL MUTATIONS IN PATIENTS OF GERIATRIC AGE WITH COMPLETE LACK OF TEETH WITH COMPLEX CLINICAL CONDITIONS FOR PROSTHETICS
97 of both sexes (males – 38 and females- 59) at the age of 75–90 years were analyzed. Among them, 58.74% patients used prosthetics firstly, 41.26% previously used complete removable dentures. During examination of the o...
Evaluation of the Systemic-Local Cytokine Profile in Patients with Pseudoexfoliation Syndrome
Purpose: to investigate the levels of inflammatory and anti-inflammatory cytokines in the aqueous humor and blood plasma of the patients with pseudoexfoliation syndrome (PES). Methods: Inflammatory cytokines (IL-6, IL-10...
Left Ventricular Remodeling Predictors in Patients with Obesity of Varying Severity
The purpose of the study was to examine clinical and anthropometric predictors of left ventricular hypertrophy in patients with isolated obesity of different stages of severity. Materials and methods. 63 people with obes...
THE INFLUENCE OF ALKILSELENONAFTIRIDIN ON LEVELS IN BLOOD OF LIPOPROTEINS HIGH, LOW AND VERY LOW DENSITY ON A BACKGROUND OF EXPERIMENTAL DIABETES
Correction of disturbances in lipid metabolism by diabetes remains a problem today. The aim of this work was to study the impact alkilselenonaftiridin (ASNR) on the dynamics of changes in the blood serum of levels lipopr...